1. Home
  2. GDL vs TIL Comparison

GDL vs TIL Comparison

Compare GDL & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDL Fund The of Beneficial Interest

GDL

GDL Fund The of Beneficial Interest

HOLD

Current Price

$8.44

Market Cap

90.7M

Sector

Finance

ML Signal

HOLD

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

HOLD

Current Price

$8.07

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDL
TIL
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.7M
74.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GDL
TIL
Price
$8.44
$8.07
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$125.00
AVG Volume (30 Days)
5.7K
21.2K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
6.02%
N/A
EPS Growth
N/A
6.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.01
$5.67
52 Week High
$8.67
$42.75

Technical Indicators

Market Signals
Indicator
GDL
TIL
Relative Strength Index (RSI) 52.82 43.12
Support Level $8.39 $7.88
Resistance Level $8.45 $9.03
Average True Range (ATR) 0.06 0.54
MACD 0.01 -0.05
Stochastic Oscillator 75.05 32.61

Price Performance

Historical Comparison
GDL
TIL

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: